Preclinical PET Neuroimaging of [C]Bexarotene
Activation of retinoid X receptors (RXRs) has been proposed as a therapeutic mechanism for the treatment of neurodegeneration, including Alzheimer's and Parkinson's diseases. We previously reported radiolabeling of a Food and Drug Administration-approved RXR agonist, bexarotene, by copper-...
Main Authors: | Benjamin H. Rotstein PhD, Michael S. Placzek PhD, Hema S. Krishnan PhD, Aleksandra Pekošak MPharm, Thomas Lee Collier PhD, Changning Wang PhD, Steven H. Liang PhD, Ethan S. Burstein PhD, Jacob M. Hooker PhD, Neil Vasdev PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi - SAGE Publishing
2016-08-01
|
Series: | Molecular Imaging |
Online Access: | https://doi.org/10.1177/1536012116663054 |
Similar Items
-
Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
by: T. Lee Collier PhD, et al.
Published: (2017-10-01) -
Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO
by: Vidya Narayanaswami PhD, et al.
Published: (2018-09-01) -
Improving PET Imaging Acquisition and Analysis With Machine Learning: A Narrative Review With Focus on Alzheimer's Disease and Oncology
by: Ian R. Duffy PhD, et al.
Published: (2019-08-01) -
Molybdenum cofactor deficiency: Neuroimaging findings
by: Mehmet Sedat Durmaz, PhD, et al.
Published: (2018-06-01) -
Multiscale Mask R-CNN–Based Lung Tumor Detection Using PET Imaging
by: Rui Zhang PhD, et al.
Published: (2019-07-01)